(Q37830724)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21250971%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

review article

1 reference

title

Optimal management of β thalassaemia intermedia (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21250971%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21250971%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Khaled M. Musallam

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21250971%20AND%20SRC:MED&resulttype=core&format=json

Maria Domenica Cappellini

20 January 2020

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21250971%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

4

David J Weatherall

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21250971%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

language of work or name

English

0 references

publication date

20 January 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21250971%20AND%20SRC:MED&resulttype=core&format=json

British Journal of Haematology

20 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21250971%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

volume

152

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21250971%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

page(s)

512-523

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21250971%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21250971%20AND%20SRC:MED&resulttype=core&format=json

Cardiac involvement in thalassemia intermedia: a multicenter study.

20 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08486.X

Thalidomide therapy in a patient with thalassemia major.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08486.X

Beta-thalassaemia and sickle cell anaemia as paradigms of hypercoagulability.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08486.X

Relationship between hypercoagulable state and erythrocyte phosphatidylserine exposure in splenectomized haemoglobin E/beta-thalassaemic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08486.X

In vivo Platelet Activation and Hyperaggregation in Hemoglobin E/β-Thalassemia: A Consequence of Splenectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08486.X

Pharmacological induction of fetal hemoglobin in sickle cell disease and beta-thalassemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08486.X

Risk of infection and death among post-splenectomy patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08486.X

Modern treatment of thalassaemia intermedia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08486.X

Complications of splenectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08486.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08486.X

Overcoming the challenge of patient compliance with iron chelation therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08486.X

Venous thromboembolism and hypercoagulability in splenectomized patients with thalassaemia intermedia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08486.X

A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08486.X

Treatment with hydroxyurea in thalassemia intermedia with paravertebral pseudotumors of extramedullary hematopoiesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08486.X

Hydroxyurea in thalassemia intermedia--a promising therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08486.X

Oral isobutyramide therapy in patients with thalassemia intermedia: results of a phase II open study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08486.X

Hemoglobin switching protocols in thalassemia. Experience with sodium phenylbutyrate and hydroxyurea.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08486.X

Relationship between genotype and phenotype. Thalassemia intermedia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08486.X

Amelioration of Sardinian beta0 thalassemia by genetic modifiers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08486.X

Biophysical characterization of the alpha-globin binding protein alpha-hemoglobin stabilizing protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08486.X

Paraspinal extramedullary hematopoiesis in patients with thalassemia intermedia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08486.X

Hydroxyurea and sodium phenylbutyrate therapy in thalassemia intermedia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08486.X

Hematologic and clinical responses of thalassemia intermedia patients to hydroxyurea during 6 years of therapy in Iran.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08486.X

Effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of patients with beta-thalassemia intermedia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08486.X

An abundant erythroid protein that stabilizes free alpha-haemoglobin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08486.X

International reproducibility of single breathhold T2* MR for cardiac and liver iron assessment among five thalassemia centers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08486.X

Long-term treatment with sildenafil in a thalassemic patient with pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08486.X

Hydroxyurea therapy in thalassemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08486.X

Treatment with hydroxycarbamide for intermedia thalassaemia: decrease of efficacy in some patients during long-term follow up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08486.X

ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American Co

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08486.X

A QTL influencing F cell production maps to a gene encoding a zinc-finger protein on chromosome 2p15.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08486.X

Pomalidomide and lenalidomide regulate erythropoiesis and fetal hemoglobin production in human CD34+ cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08486.X

A genome-wide association identified the common genetic variants influence disease severity in beta0-thalassemia/hemoglobin E

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08486.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08486.X

21 January 2018

The beta-thalassemias

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08486.X

Studies in haemoglobin E beta-thalassaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08486.X

Effects of N-acetylcysteine on dense cell formation in sickle cell disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08486.X

Do alpha deletions influence hydroxyurea response in thalassemia intermedia?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08486.X

Vitamin E supplementation reduces oxidative stress in beta thalassaemia intermedia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08486.X

Iron absorption and loading in beta-thalassaemia intermedia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08486.X

Clinical trial of deferiprone iron chelation therapy in beta-thalassaemia/haemoglobin E patients in Thailand

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08486.X

Absence of cardiac siderosis despite hepatic iron overload in Italian patients with thalassemia intermedia: an MRI T2* study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08486.X

Human fetal hemoglobin expression is regulated by the developmental stage-specific repressor BCL11A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08486.X

Developmental and species-divergent globin switching are driven by BCL11A

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08486.X

Regression of extramedullary haemopoiesis and augmentation of fetal haemoglobin concentration during hydroxyurea therapy in beta thalassaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08486.X

Fetal haemoglobin augmentation in E/beta(0) thalassaemia: clinical and haematological outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08486.X

Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08486.X

Pulmonary thromboembolism in beta-thalassemia intermedia: are we aware of this complication?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08486.X

Thalassemia intermedia: revisited

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08486.X

Thalassemia and hypercoagulability

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08486.X

Iron overload in thalassaemia intermedia: reassessment of iron chelation strategies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08486.X

The hypercoagulable state in thalassemia intermedia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08486.X

Iron overload: consequences, assessment, and monitoring.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08486.X

Splenectomy and thrombosis: the case of thalassemia intermedia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08486.X

Overview on practices in thalassemia intermedia management aiming for lowering complication rates across a region of endemicity: the OPTIMAL CARE study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08486.X

Asymptomatic brain magnetic resonance imaging abnormalities in splenectomized adults with thalassemia intermedia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08486.X

Oral supplements of vitamin E improve measures of oxidative stress in plasma and reduce oxidative damage to LDL and erythrocytes in beta-thalassemia intermedia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08486.X

Cytoprotective effects of the antioxidant phytochemical indicaxanthin in beta-thalassemia red blood cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08486.X

Improving adherence with deferoxamine regimens for patients receiving chronic transfusion therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08486.X

Genome-wide association study shows BCL11A associated with persistent fetal hemoglobin and amelioration of the phenotype of beta-thalassemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08486.X

A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08486.X

Continuous increase in erythropoietic activity despite the improvement in bone mineral density by zoledronic acid in patients with thalassemia intermedia-induced osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08486.X

Continuous improvement of bone mineral density two years post zoledronic acid discontinuation in patients with thalassemia-induced osteoporosis: long-term follow-up of a randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08486.X

Treatment with deferasirox (Exjade) effectively decreases iron burden in patients with thalassaemia intermedia: results of a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08486.X

The HBS1L-MYB intergenic interval associated with elevated HbF levels shows characteristics of a distal regulatory region in erythroid cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08486.X

Phenotype-genotype relationships in monogenic disease: lessons from the thalassaemias.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08486.X

2003 William Allan Award address. The Thalassemias: the role of molecular genetics in an evolving global health problem

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08486.X

Butyrate increases the efficiency of translation of gamma-globin mRNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08486.X

MRI R2 and R2* mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08486.X

Pregnancy outcome in patients with -thalassemia intermedia at two tertiary care centers, in Beirut and Milan

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08486.X

Correlation of liver iron concentration determined by R2 magnetic resonance imaging with serum ferritin in patients with thalassemia intermedia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08486.X

Levels of non-transferrin-bound iron as an index of iron overload in patients with thalassaemia intermedia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08486.X

Magnetic resonance evaluation of hepatic and myocardial iron deposition in transfusion-independent thalassemia intermedia compared to regularly transfused thalassemia major patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08486.X

10.1111/J.1365-2141.2010.08486.X

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21250971%20AND%20SRC:MED&resulttype=core&format=json

release_tejxxupb3vdh5bkhk76temzwia

20 January 2020

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/tejxxupb3vdh5bkhk76temzwia

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference